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Summary: Interleukin 1, a multifunctional cytokine, plays a central role in inflammatory processes and
induction of the immune response. Target cells possess 200 — 5000 (or more) interleukin 1 receptors per cell,
but they exhibit a full biological response when only 1 —2% of these receptors are occupied by interleukin
la or I . Methotrexate has been reported to be beneficial in several inflammatory and autoimmune diseases.
On the other hand, many of these diseases are known to share an overproduction of interleukin 1. It has
been demonstrated that methotrexate has no influence on the interleukin 1 synthesis, so we focused our
attention on the ability of methotrexate to interfere with the binding of interleukin 1 β to the interleukin 1
receptor. The experiments were performed on monocytes, lymphocytes and granulocytes using a recombinant
human cytokine probe. Methotrexate led to an astonishing decrease in the binding of interleukin 1 β to the
interleukin 1 receptor of peripheral blood cells, whereas methylprednisolone and indomethacin were not
inhibitory. The inhibitory effect of methotrexate was dose dependent. An excess of interleukin I abolished
the inhibition of cytokine binding by methotrexate. We also demonstrated that methotrexate does not affect
the integrity of the interleukin 1 receptor or of the target cells. Our results demonstrate that methotrexate
blocks the interleukin l -interleukin 1 receptor pathway. Methotrexate is therefore another interleukin 1
inhibitor and a clinically efficient anticytokine.
but exert a full biological effect when only 1 —2% of
Interleukin 1 is represented by two distinct cytokines, these receptors are occupied by interleukin 1 (2).
interleukin la and interleukin I polypeptides, which ^ , 1 1 · , . , * · , ,, . - - . - , . ; Two molecular biological mechanisms control the ac-bmd to the same receptors, interleukin 1 receptor . . r. ^ , ,. Λ - ,. . . Γ . ^ , .. Λ
T j · * ι " ι · * ' T T -m. tivity of interleukin 1: the adjustment of interleukin 1type I and interleukin 1 receptor type II. The two ' . , 4, , Α. Γ . ., , . ^^ , . , ., · ι * . , · , · synthesis and the regulation of signal transduction bycytokines have identical biological properties. · r ·*ι. *ιΓ u· j- *· * ι Ί · 40 ^ ^ interference with the binding of interleukin 1 to its
Binding studies in a variety of cells have shown that receptor on target cells. The binding of interleukin 1
interleukin la exhibits a greater affinity to the inter- to the interleukin 1 receptor is prevented by natural
leukin 1 receptor type I (MT 80 000) and interleukin 1 β interleukin 1 inhibitors such as the interleukin 1 re-
exerts a greater affinity to the interleukin 1 receptor ceptor antagonist, which competes with interleukin 1
type II (MT 60 000). The interleukin 1 receptor type I for the interleukin 1 receptor, or by the soluble inter-
is found on T-cells, fibroblasts, keratinocytes, endo- leukin 1 receptor which binds directly to interleukin 1
thelial cells and chondrocytes; the interleukin 1 recep- (1, 2). Other described interleukin 1 inhibitors are
tor type II is found on B-cells, neutrophils and mono- epidermal cell-contra-interleukin 1 which is induced
cytes (1). It has been reported that target cells possess by UV-B radiation in the epidermis (3), and the cy-
200—5000 (ore more) interleukin 1 receptors per cell tokine transforming growth factor l (4). Because of
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the great affinity of the target cells for interleukin 1,
an excess of interleukin 1 receptor antagonist must
be present to block the interleukin 1-induced biolog-
ical responses.
Independent of its antiproliferative effect in high doses
(5, 6), methotrexate (4-amino-4-deoxy-N10-methyl-
pteroylglutamic acid) exerts well documented antiin-
flammatory and immunoregulatory activity in low
doses, but its mechanism of action is not clear.
While methotrexate has no demonstrable influence on
the interleukin 1 production (7) and at the same time
there are clinical and experimental references to an
antiinflammatory function of methotrexate, the ques-
tion arises whether it might act via interleukin 1
antagonism. We focussed our attention on the binding
of interleukin 1 β to its receptor on target cells in the
presence of methotrexate, in order to examine whether
methotrexatahas the ability to block the interleukin 1-
interleukin 1 receptor pathway.
Materials and Methods
Materials
Phycoerythrin labelled human interleukin I was obtained from
Hermann Biermann Diagnostica GmbH Bad Nauheim, Ger-
many, methotrexate was obtained from Lederle GmbH & Co.
Wolfratshausen, Germany, methylprednisolone (Urbason®)
from Hoechst AG Frankfurt a. M., Germany, indomethacin
(Vonum®) from Econerica GmbH Puchheim/M nchen, Ger-
many. Phycoerythrin-labelled monoclonal antibodies: mouse
anti-human CDS, mouse anti-human CD4, mouse anti-human
CDllb, mouse anti-human CD14, mouse anti-human CD19,
mouse anti-human CD25 were obtained from Becton Dickinson
GmbH Heidelberg, Germany. The flow cytometer (FACScan)
apparatus and FACS lysing solution were from Becton Dick-
inson GmbH Heidelberg, Germany.
Cytokine probe — principle of the method
Cells were incubated with phycoerythrin labelled interleukin 1 β
which bound to specific cellular interleukin 1 receptors. Un-
bound interleukin I was then washed from the cells. Cells
expressing the interleukin 1 receptor were fluorescently stained.
The intensity of fluorescence was directly proportional to the
density of the receptors. Phycoerythrin labelled interleukin l -
binding receptor density was then determined by FACS analysis
using 488 nm wavelength laser excitation. The specificity of the
reaction of phycoerythrin labelled interleukin I was demon-
strated by blocking the staining of the cells by pretreatment
with a 100-fold molar excess of unlabeled interleukin I prior
to incubation with phycoerythrin labelled interleukin I .
The binding ability of interleukin I to the interleukin 1 recep-
tor on monocytes, lymphocytes and granulocytes was analysed
in blood samples from twenty-five healthy volunteers as follows:
Interleukin I binding assay
Whole blood was collected in evacuated tubes containing EDTA
as the anticoagulant. Phycoerythrin labelled interleukin I (32.5
ng) was added to 25 μΐ EDTA blood for a total reaction volume
of 50 μΐ and incubated for 60 minutes at 4 °C. The crythrocytes
were then lysed using FACS lysing solution. Unbound phyco-
erythrin labelled interleukin I was removed by washing the
cells with 0.02 mol/1 phosphate buffered 9 g/1 saline solution
pH 7.4 and by centrifuging the cells £t 1000 g for five minutes.
The cells were resuspended in phosphate buffered saline for
final FACS analysis.
Interleukin I inhibitory assay
Phycoerythrin labelled interleukin I (32.5 ng) was added to
500 μg methotrexate or to 50 μg indomethacin or to 800 μg
methylprednisolone in a total reaction volume of 25 μΐ and
incubated for 30 minutes at room temperature. The methotrex-
ate sample was incubated in opaque tubes because methotrexate
is photosensitive. Following this incubation, 25 μΐ EDTA blood
was added to give a total reaction volume of 50 μΐ and incubated
for 60 minutes at 4 °C. The assay was then continued as de-
scribed above. The inhibitory assay was repeated using 12.5 —
500 μg methotrexate, 200-1200 μg methylprednisolone or 50—
120 μg indomethacin. The interaction of methotrexate, meth-
ylprednisolone or indomethacin with the binding of
interleukin 1 β to its receptor on monocytes, lymphocytes and
granulocytes was determined from the decrease in intensity of
fluorescence and percentage of cells binding interleukin 1 β.
Controls were carried out with a panel of phycoerythrin-con-
jugated mouse antHmman monoclonal antibodies against yar-
ious leukocyte differentiation antigens and 500 μg methotrexate,
in order to determine whether methotrexate can quench the
fluorescence signal of phycoerythrin.
Interleukin 1 receptor integrity assay
An inhibitory assay was started using 32.5 ng phycoerythrin
labelled interleukin I , 500 μg methotrexale and 25 μΐ EDTA
blood as described above. The assay was stopped after the
incubation step with the blood for 60 minutes at 4 °C. The cells
were washed 3 times with phosphate buffered saline, then re-
suspended in phosphate buffered saline for a total volume of
25 μΐ and taken for the binding assay as described above. The
results were compared with those of the previously performed
inhibitory and binding assays.
Flow cytometric analysis
For each measurement 104 cells were acquired. The quantitative
presentation of the data was demonstrated in dot-plot analysis
and histograms. The intensity of the fluorescence and the per-
centage of interleukin I binding cells were calculated.
Statistical analysis
The data from twenty-five binding and inhibitory assays was
checked for significance as follows:
The displacement of the fluorescence intensity due to a dimin-
ished phycoerythrin labelled interleukin 1 β binding to its recep-
tor, presented quantitatively in form of histograms, was ana-
lysed using the Kolmogofov-Smirnov statistical test (8). Starting
from the two histograms for the same sample before and after
additional methotrexate, we computed the sample probability
distribution functions Fn,(x) and Fn2(x), given by:
Xr xr
Fni(xr) = Σ fn,(x) and Fn2(xr) = Σ fn2(x)
where xr is the abscissa value. In a* how system the abscissa
represents 1024 channels, so that 0 < xr < 1024. The graphical
presentation of Fn,(xr) and Fn2(xr) are the summation curves.
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The statistic D was also calculated. D indicates graphically the
maximum vertical deplacement between the two summation
curves and is given by: D = max [Fnt(x) —Fn2(x)].
The Kolmogorov-Smirnov statistical test was applied separately
for monocytes, lymphocytes and granulocytes.
Data for the mean intensity of fluorescence of the phycoerythrin
labelled interleukin I binding monocytes, lymphocytes and
granulocytes from binding and inhibitory assays were analysed
by linear regression. The statistical significance of the regression
coefficients and of the statistical D were evaluated by using the
two-sided Student t test.
Results
Expression of the interleukin 1 receptor
type II by monocytes, lymphocytes and gran-
ulocytes in peripheral blood
The lymphocytes in peripheral blood show some bind-
ing of interleukin 1 β, and therefore express the inter-
leukin 1 receptor type II. The percentage of interleu-
kin l -binding lymphocytes of healthy volunteers var-
ies from 3.1 to 32.4%. Distinctly more interleukin I
was bound by monocytes than by lymphocytes.
Monocytes regulary expressed the interleukin 1 recep-
tor type II, reaching range of 59.6 — 93.7% of the
cells.
Only 0.2 — 6.9% of the granulocytes of healthy vol-
unteers expressed the interleukin 1 receptor type II.
Methotrexate, but not methylprednisolone
or indomethacin, blocks the binding of inter-
leukin I to the interleukin 1 receptor on
monocytes, lymphocytes and granulocytes in
peripheral blood
The binding of interleukin I to the interleukin 1
receptor of all monocytes, lymphocytes and gran-
ulocytes was markedly decreased in the presence of
500 μg methotrexate. Both the percentage and inten-
sity of fluorescence of the interleukin l -binding cells
were decreased (fig. la, b). The decrease of fluores-
cence intensity as visualized by histograms (fig. 2a, b,
c) was analysed with the Kolmogorov-Smirnov statis-
tical test for the analysis of histograms from flow
systems.
The results of computed sample probability distri-
bution functions starting from the histograms in fig-
ures 2a, b, c are seen in figures 3a, b, c. They dem-
onstrate the displacement of the fluorescence intensity
due to diminished phycoerythrin labelled interleu-
kin 1 β binding to the interleukin 1 receptor on target
cells in the presence of 500 μg methotrexate. The
displacement between the two summation curves was
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Fig. 1. Dot-plot analysis of phycoerythrin labelled interleukin
l -binding monocytes without methotrexate (a) and
with 500 μg methotrexate (b).
lymphocytes and granulocytes. In addition, the mean
fluorescence intensity of phycoerythrin labelled inter-
leukin I binding cells before and after 500 μg meth-
otrexate application was measured in all twenty-five
binding and inhibitory assays. The data was analysed
by linear regression, separately for monocytes, lym-
phocytes and granulocytes (fig. 4a, b, c). The linear
regression indicated a coefficient r = 0.7 (p < 0.001)
for monocytes, r = 0.74 (p < 0.001) for lymphocytes
and r = 0.78 (ρ < 0.001) for granulocytes, thus dem-
onstrating the constant and significant ability of
methotrexate to block the binding of interleukin 1 β
to its receptor.
Methylprednisolone and indomethacin had no influ-
ence on the binding of interleukin I to its receptor
in concentrations ranging from 200—1200 μg for
methylprednisolone and 50 — 125 μg for indometha-
cin. Controls consisting of monocytes, lymphocytes
and granulocytes labelled with phycoerythrin-conju-
gated monoclonal antibodies against the leukocyte
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out ( ) and with ( ) additional methotrexate. The
decreased fluorescence intensity is due to a diminished
binding of interleukin 1 β to its receptor in the presence
of methotrexate ( ).
a. Monocytes; b. Lymphocytes; c. Granulocytes
Channel Number
Fig. 3. Kolmogorov-Smirnov test for the analysis of the histo^
grams. Summation curves,
a. Monocytes; b. Lymphocytes; c. Granulocytes
differentiation antigens CD3, CD4, CDllb, CD14,
GDI 9, CD25 with and without additional methotrex-
ate showed no changes of fluorescence intensity when
500 μg methotrexate and phycoerythrin-conjugated '
monoclonal antibodies were used simultaneously.
These controls showed that methotrexate does not
quench the fluorescence signal of phycoerythrin.
The ability of methotrexate to interfere with the bind-
ing of interleukin I to the interleukin 1 receptor on
target cells was dose dependent (fig. 5). The analysed
quantity was the percentage of interleukin 1 β binding
cells. The cell population stained by phycoerythrin
labelled interleukin 1 β without methotrexate was re^
garded as 100% positive. Using methotrexate concen-
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Fig. 4. Analysis of the data by means of linear regression. Investigated quantity: the mean intensity of fluorescence of phycoerythrin
labelled interleukin l -binding cells.
a. Monocytes Regression equation: y = 6.4 + 0.33x;
b. Lymphocytes Regression equation: y = 9.98 + 0.25x;
c. Granulocytes Regression equation: y = 38.45 + 0.31x.
trations of 12.5 — 500 μ£ in the inhibitory assay, we
demonstrated that a 50% inhibition of the interleu-
kin I binding is achieved by 75 μg methotrexate for
lymphocytes, by 287.5 μ§ methotrexate for granulo-
cytes and by 350 μ§ methotrexate for monocytes. The
assay indicated not only a dose dependent effect of
methotrexate on the binding of interleukin I to the
interleukin 1 receptor but also a dependence on the
cell population. The interleukin I antagonism of
methotrexate was first perceptible on lymphocytes
then on granulocytes and then on monocytes.
The effect of methotrexate was reversible. Incubation
of 500 μg methotrexate with a sixfold interleukin 1 β
concentration in the inhibitory assay abolished the
ability of methotrexate to block the activity of the
cytokine. In these circumstances, interleukin I be-
came bound to the interleukin 1 receptor on target
cells. The fluorescence intensity and percentage of
interleukin 1 β binding cells were comparable to those
in the original binding assay.
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Fig. 5. The effect of methotrexate on the binding of interleukin
Iß to its receptor is dose-dependent.





Methotrexate blocks the activity of interleu-
kin Iß without affecting the integrity of the
interleukin 1 receptor on target cells
In the interleukin 1 receptor integrity assay we dem-
onstrated that monocytes, lymphocytes and granu-
locytes which bound very small amounts of interleu-
kin l ß in the presence of methotrexate, bound inter-
leukin Iß again after removing methotrexate and in-
terleukin l ß from the solution. The binding, measured
by fluorescence intensity and percentage of cells
stained by phycoerythrin labelled interleukin l ß, was
practically identical to that in the original binding
assay. Thus, 500 g methotrexate are able to block
the binding of 32.5 ng interleukin l ß without affecting
the integrity of the interleukin 1 receptor or of the
target cells.
Discussion
We investigated the binding of interleukin l ß to the
interleukin 1 receptor on the cell surface of mono-
cytes, lymphocytes and granulocytes of healthy vol-
unteers in the presence of methotrexate, by means of
phycoerythrin-conjugated cytokine and FACS anal-
ysis. According to the literature, the interleukin 1
receptor type II has regulary been found on mono-
cytes, whereas, contrary to our expectations, it was
expressed by only 0.2-6.9% of granulocytes.
The binding studies provided direct experimental ev-
idence that methotrexate blocks the binding of inter-
leukin l ß to its receptor on target cells. This effect is
dose-dependent. Therefore methotrexate is able to
control the interleukin 1 activity by blocking signal
transduction between cytokine and target cells.
Methotrexate is therefore another interleukin 1 inhib-
itor such as interleukin 1 receptor antagonist, soluble
interleukin 1 receptor or epidermal cell-contra-inter-
leukin 1. Furthermore, the results of the interleukin
1 receptor integrity assay provided experimental evi-
dence that methotrexate functions as an interleukin 1
inhibitor without affecting the integrity of the target
cells or the interleukin 1 receptor.
Initially described as a product of activated phago-
cytic cells, it is now known that interleukin 1 is syn-
thesized by a wide variety of cells. These include
circulating blood monocytes, splenic macrophages,
bone marrow adherent cells, hepatic Kupffefs cells,
peritoneal macrophages, pulmonary alveolar macro-
phages, as well as non-phagocytic cells such as kera-
tinocytes, Langerhans" cells of the skin, endothelial
and smooth muscle cells, corneal, gingival and thymic
epithelial cells, astrocytes and microglial cells in the
brain, osteoclasts and synovial fibroblasts. B-cells and
natural killer cells express interleukin 1. Various epi-
thelial cells, neurons and adrenal cells from healthy
subjects contain interleukin 1 (9). Its production can
be stimulated by agents such as immunocomplexes,
complement components, microbial products such as
endotoxin, plant lectins or antigens (10). Interleukin 1
is a proinflammatory cytokine and its pyrogenic effect
due to prostaglandin release is well known. Interleu-
kin 1 is a co-growth factor for keratinocytes impli-
cated in acanthosis (11), it stimulates fibroblasts to
synthesize and release collagenase and prostaglandins
and stimulates endothelial cells to upregulate adhesion
molecules (12, 13). Interleukin 1 stimulates the im-
mune system directly by activating lymphocytes and
indirectly by inducing other cytokines. Interleukin 1
induces in T-cells the production of interleukin 2 as
well as the expression of interleukin 2 receptors. To-
gether with interleukin 4 and interleukin 6 interleu-
kin 1 activates B-cells and contributes to the forma-
tion of antibodies. In fibroblasts, endothelial cells,
macrophages and lymphocytes, interleukin 1 stimu-
lates the production of interferons and haematopoetic
colony-stimulating factors. Interleukin 1 and tumour
necrosis factor induce the production of each other
from monocytes, fibroblasts and endothelial cells. In-
terleukin 1 stimulates its own production in mono-
cytes (14), in smooth muscle cells (15) and in endo-
thelial cells (16). This effect depends upon the con-
centration of interleukin 1. Furthermore interleukin
1 induces the production of interleukin 8 in dermal
fibroblasts, a neutrophil-activating cytokine with a
major role in psoriasis (17), and also in endothelial
cells (18). Interleukin 1 is known to induce the syn-
thesis of interleukin 3 and interleukin 6 and together
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 10
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with interleukin 2 and α Interferon it activates the
natural killer cells (19). An increased interleukin 1
production is implicated in several diseases such as
rheumatoid arthritis (9, 20), septic shock (1, 9), graft
versus host disease (21), transplant rejection (22),
acute and chronic leukaemia (9, 23), psoriasis (24,
25), tuberculosis (26), leprosy (27), cutaneous T-cell
lymphoma (28), inflammatory bowel disease (9) and
asthma (9). Patients with systemic lupus erythema-
tosus have a spontaneous interleukin 1 production by
B-cells. B precursor cells express the interleukin 1
receptor. The findings suggest an autocrine mecha-
nism of conversion of precursor B-cells to imrmmo-
globulin-producing cells in which interleukin 1 plays
a key role (29). Several clinical studies have shown
that low dose methotrexate is efficacious in the treat-
ment of inflammatory and autoimmune diseases such
as rheumatoid arthritis (30), psoriasis and psoriatic
arthritis (31, 32), inflammatory bowel disease (33),
systemic lupus erythematosus (34), primary biliary
cirrhosis (35), graft versus host disease (36), but also
Sezary syndrome (37) and corticosteroid-dependent
asthma (38), diseases which are meanwhile all known
to share an overproduction of interleukin 1. The onset
of the antiinflammatory effect of methotrexate was
rapid in all treated patients.
Although the mechanism by which high dose metho-
trexate alters cellular biochemical reactions and exerts
its cytotoxic effect is well characterized, the mecha-
nism by which low dose methotrexate interferes with
the ongoing inflammatory and immune reactions in
such a wide spectrum of diseases remained elusive. In
order to demonstrate the presumed immunomodula-
tory effect of methotrexate several models have been
elaborated. Valuable contributions were made by Se-
gal et al. (7) who observed that there was no demon-
strable effect of methotrexate on interleukin 1 syn-
thesis in vitro or in rheumatoid arthritis patients and
mice treated with methotrexate. However methotrex-
ate had an inhibitory effect on two functions of in-
terleukin 1 in vitro. Several other studies suggest that
neutrophil chemotaxis is depressed in the presence of
methotrexate, indicating a direct or indirect effect of
methotrexate on neutrophils with positive conse-
quences on psoriatic lesions (39—41). Johnson et al.
(42) demonstrated in an adjuvant arthritis rat model
that methotrexate, indomethacin and prednisolone
are efficient antiinflammatory drugs, but only metho-
trexate had the ability to prevent systemic activation
and local accumulation of inflammatory cells,
whereas indomethacin and prednisolone suppressed
only the ongoing local inflammatory process.
We demonstrated that methotrexate blocks the bind-
ing of interleukin I to the interleukin 1 receptor on
target cells. The function of methotrexate as an in-
terleukin 1 inhibitor explains its clinical efficiency in
a wide spectrum of diseases, which in the meantime
have been shown to have in common an overproduc-
tion of interleukin 1. The interleukin 1 antagonism of
methotrexate leads to a rapid abolition of the ongoing
stimulation of the immune system. Both the direct
activation of lymphocytes and the cytokine cascade
are interrupted. Because of the diversity of cells af-
fected by interleukin 1, methotrexate plays a key role
in the therapy as an interleukin 1 inhibitor that spe-
cifically modulates the interleukin 1 response without
affecting the interleukin 1 receptor or cellular func-
tions.
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